Reference no: EM132133912

1) Analyses mentioned in the case suggested that the market for in-house diagnostics would grow in the next five years.

A) True

B) False

2) Veterinary clinics found that having diagnostic equipment in-house led to a lower volume of testing.

A) True

B) False

3) Bergerac needed to make a decision quickly about in-house development or external acquisition due to inconsistency in the supply of cartridges.

A) True

B) False

4) Which of the following are true about Bergerac's competitors? (select all that apply)

A) Bergerac's OmniVue product was at a higher price point than the comparable system offered by Abaxis

B) Bergerac was the market share leader in the veterinary diagnostics instruments market

C) Idexx had the largest product line and the best-established distribution network and sales force

D) Bergerac saw an opportunity for itself to capture market share in small- and medium-sized veterinary practices

5) Which of the following statements are true of Bergerac's cartridge sourcing and production processes? (select all that apply)

A) It was difficult for cartridge suppliers to respond to unexpected spikes in demand

B) Despite dependencies on petrochemical prices, plastics suppliers enjoyed a market with very high margins

C) Bergerac sourced the plastic parts for its cartridges from only one supplier--GenieTech

D) Bergerac had to carry more inventory than they would like

6) Which of the following statements are true of the build vs. buy decision? (select all that apply)

A) Bergerac's business already accounted for more than 90% of GenieTech's revenue

B) McCarthy's analysis assumed a ~8% annual growth in production demand in the years ahead

C) McCarthy calculated more annual savings with the in-house option at current rates of production

D) In the "build" option, the machinery Bergerac would use would be less efficient than what GenieTech uses